Short Original Article
Clinical application of anti-nuclear antibody in the karyotype of HEp-2 cell
Tao Yue, Zhu Yijia, Zhu Wenbo, Zheng Qisi, Zhai Junbin, Ning Mingzhe
Published 2019-12-15
Cite as Chin J Rheumatol, 2019,23(12): 845-846,C4. DOI: 10.3760/cma.j.issn.1007-7480.2019.12.010
Abstract
ObjectiveTo explore the clinical application of new nuclear pattern deoxyribonucleic acid (DNA) topoisomerase type Ⅰ (AC-29).
MethodsFour clinical specimens of the department of clinical laboratory of the Affiliated Drum Tower Hospital of Nanjing University Medical College were selected. The anti-nuclear antibody spectrum (IgG) was detected by immunoblotting, and the anti-nuclear antibody IgG was detected by indirect immunofluorescence. The results were observed and recorded.
ResultsAmong the 4 specimens, the anti-Scl-70 antibody was positive, and the anti-nuclear antibody human epidermoid carcinoma cell line (HEp-2) pattern was AC-29.
ConclusionAC-29 is a newly defined HEp-2 IFA pattern of inter-national consensus on antinuclear antibody pattern (ICAP). Domestic inspectors should study its performance under fluorescence microscopy, understand its clinical significance, and provide accurate test reports for clinicians.
Key words:
Antibodies, anti-nuclear; Human epidermoid carcinoma cell line-2 cell; Fluorescent, antibody technique, indirect; Anti Scl-70 antibody; DNA Toposomerases, typeⅠ
Contributor Information
Tao Yue
Department of Clinical Laboratory, Affiliated Drum Tower Hospital of Nanjing University Medical College, Jiangsu 210008, China
Zhu Yijia
Zhu Wenbo
Zheng Qisi
Zhai Junbin
Ning Mingzhe